Armanezumab
Armanezumab is a monoclonal antibody that targets and inhibits tau protein, and it specifically binds to the exposed N-terminal domain of pathological tau protein. Armanezumab can be used in relevant studies on Alzheimer's disease, frontotemporal dementia, and Pick's disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human
Armanezumab (3-243 nM) binds recombinant human 0N/4R tau protein with a high affinity, characterized by an equilibrium dissociation constant of 38.8 nM[1].
Armanezumab (0.02-12.5 μM; 1.5 h) specifically targets the PRQEF epitope (amino acids 4-8) of tau2-18, with amino acids 6 (glutamine) and 7 (glutamic acid) being essential for binding[1].
Armanezumab (1 μM; 16 h) partially protects SH-SY5Y human neuroblastoma cells from tau oligomer-mediated cytotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SH-SY5Y human neuroblastoma cells
-
Concentration:1 μM (Armanezumab pre-incubated with 0.5 μM tau oligomers)
-
Incubation Time:16 h (cell incubation with oligomer-Armanezumab mixture)
-
Result:Restored SH-SY5Y cell viability to 89% compared to 36% viability in cells treated with tau oligomers alone, protecting cells from tau oligomer-mediated cytotoxicity.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:THY-Tau22 tau transgenic mice (6-month-old)[1]
-
Dosage:2 μg
-
Administration:intracranial injection (hippocampus and cortex); single dose
-
Result:Reduced total tau (HT7-stained) and phosphorylated tau species including pThr212, pSer214, pSer396/pSer404 (PHF1-stained), pThr212/pSer214 (AT100-stained), pThr231 (AT180-stained), and pSer202/pThr205 (AT8-stained) in the ipsilateral hemisphere compared to contralateral control IgG-injected hemisphere.
Confirmed neuronal integrity at injection sites via anti-NeuN staining.
Tau
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[Armanezumab]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Armanezumab Related Classifications
HY-P992057 Related Classifications
Powered by Bioz